3-AP and Cytarabine in Treating Patients With Hematologic Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00064090
First received: July 8, 2003
Last updated: July 17, 2013
Last verified: August 2008

July 8, 2003
July 17, 2013
March 2003
September 2004   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00064090 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
A Phase I Study of Triapine and Cytarabine in Patients With Hematologic Malignancies

RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die. 3-AP may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and may help cytarabine kill more cancer cells by making them more sensitive to the drug.

PURPOSE: Phase I trial to study the effectiveness of combining cytarabine with 3-AP in treating patients who have relapsed or refractory hematologic cancer.

OBJECTIVES:

  • Determine the feasibility, tolerability, and toxic effects of 3-AP in combination with cytarabine in patients with hematologic malignancies.
  • Determine the maximum tolerated dose and phase II dose of cytarabine in this regimen in these patients.
  • Determine the biological effects of 3-AP and its interaction with cytarabine in these patients.

OUTLINE: This is a pilot, dose-escalation study of cytarabine.

Patients receive 3-AP IV over 6 hours followed by cytarabine IV over 18 hours on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a response may receive an additional course as consolidation therapy.

Cohorts of 3-6 patients receive escalating doses of cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 10 patients receive treatment at that dose.

PROJECTED ACCRUAL: Approximately 20-25 patients will be accrued for this study.

Interventional
Phase 1
Primary Purpose: Treatment
  • Leukemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Drug: cytarabine
  • Drug: triapine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
January 2008
September 2004   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of 1 of the following hematologic malignancies:

    • Acute myeloid leukemia
    • Acute lymphoblastic leukemia
    • Chronic myelogenous leukemia (CML)
    • CML in blast crisis
    • Chronic lymphocytic leukemia
    • High-risk* myelodysplastic syndromes, including the following:

      • Refractory anemia with excess blasts (RAEB)
      • RAEB in transformation
      • Chronic myelomonocytic leukemia NOTE: *High-risk myelodysplasia defined as having an International Performance Scoring System score of at least 1.5, based on adverse cytogenetics, greater than 10% blasts in marrow, and cytopenias in at least 2 lineages
  • Relapsed or refractory disease
  • Ineligible for higher priority protocols

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • More than 2 months

Hematopoietic

  • See Disease Characteristics

Hepatic

  • Bilirubin no greater than 2.0 mg/dL (unless considered due to malignancy)
  • ALT or AST no greater than 3 times upper limit of normal
  • Chronic hepatitis allowed

Renal

  • Creatinine no greater than 2.0 mg/dL (unless considered due to malignancy)

Cardiovascular

  • No myocardial infarction within the past 3 months
  • No symptomatic coronary artery disease
  • No arrhythmias (other than atrial fibrillation or flutter) requiring treatment
  • No uncontrolled congestive heart failure

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Concurrent infections under active treatment with and controlled by antibiotics allowed
  • No other concurrent life-threatening illness
  • No mental deficit or psychiatric history that would preclude giving informed consent or complying with protocol

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • At least 1 week since prior growth factors, including the following:

    • Epoetin alfa
    • Filgrastim (G-CSF)
    • Sargramostim (GM-CSF)
    • Interleukin-3
    • Interleukin-11
  • No concurrent anticancer immunotherapy

Chemotherapy

  • At least 72 hours since prior hydroxyurea
  • Recovered from prior chemotherapy
  • No other concurrent anticancer chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • At least 2 weeks since prior radiotherapy
  • No concurrent anticancer radiotherapy

Surgery

  • Not specified

Other

  • At least 3 weeks since prior myelosuppressive cytotoxic agents (in the absence of rapidly progressing disease)
  • At least 1 week since prior nonmyelosuppressive therapy
  • No other concurrent standard or investigational therapy for the malignancy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00064090
VION-CLI-032, CDR0000306465, MDA-DM-030096
Not Provided
Not Provided
Vion Pharmaceuticals
Not Provided
Study Chair: Mario Sznol, MD Vion Pharmaceuticals
National Cancer Institute (NCI)
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP